Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Ludotadipep Phase I in mCRPC
NCT04509557Phase 1Completed
- Sponsor
- FutureChem Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ludotadipep in metastatic castration-resistant prostate cancer (mCRPC), sponsored by FutureChem Co., Ltd. Primary endpoint: Dose-limiting toxicity. Started Oct 2020; status: completed.
02
Drugs
Ludotadipep
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04509557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509557.